Data 11 November, Hai Li Biology announced that the company plans to sell 76.07% of the equity of Yangling Jinhai held by its controlling shareholder, Shanghai Haoyuan. After the completion of this transaction, the company will no longer directly hold equity in Yangling Jinhai, and Yangling Jinhai will no longer be included in the company's consolidated financial statements; and the company will recover all loans to Yangling Jinhai and repay the relevant bank loans.
Lihat Asli
Halaman ini mungkin berisi konten pihak ketiga, yang disediakan untuk tujuan informasi saja (bukan pernyataan/jaminan) dan tidak boleh dianggap sebagai dukungan terhadap pandangannya oleh Gate, atau sebagai nasihat keuangan atau profesional. Lihat Penafian untuk detailnya.
海利生物：berencana untuk menjual 76,07% saham Yangling Jinhai kepada pemegang saham pengendali Shanghai Haoyuan
Data 11 November, Hai Li Biology announced that the company plans to sell 76.07% of the equity of Yangling Jinhai held by its controlling shareholder, Shanghai Haoyuan. After the completion of this transaction, the company will no longer directly hold equity in Yangling Jinhai, and Yangling Jinhai will no longer be included in the company's consolidated financial statements; and the company will recover all loans to Yangling Jinhai and repay the relevant bank loans.